Changchun High-tech: Subsidiary GenSci140's application for clinical trial registration of domestically produced injectable drugs approved.

Changchun High-tech announced that its subsidiary, Jinsai Pharmaceuticals, has received approval from the National Medical Products Administration for the clinical trial application for the domestic production of the injection drug GenSci140. GenSci140 is a novel dual-site antibody-drug conjugate targeting the folate receptor alpha subtype developed independently by Jinsai Pharmaceuticals, and is intended for the treatment of locally advanced or metastatic solid tumors. Preclinical studies have shown that GenSci140 exhibits significant anti-tumor effects in various tumor models. This approval will help the company expand its business scope, optimize product structure, and enhance its core competitiveness.